These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16159420)

  • 1. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
    Wakelee HA; Sikic BI
    Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S6-12. PubMed ID: 16159420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
    Huang CH; Treat J
    Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cytotoxic agents: epothilones.
    Goodin S
    Am J Health Syst Pharm; 2008 May; 65(10 Suppl 3):S10-5. PubMed ID: 18463327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epothilones in the treatment of cancer.
    Larkin JM; Kaye SB
    Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.
    Edelman MJ; Shvartsbeyn M
    Clin Lung Cancer; 2012 May; 13(3):171-80. PubMed ID: 22133291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical applications of epothilones: a review of phase II studies.
    Larkin JM; Kaye SB
    Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy.
    Lee JJ; Kelly WK
    Nat Clin Pract Oncol; 2009 Feb; 6(2):85-92. PubMed ID: 19048010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
    Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
    Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
    Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
    J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of topoisomerase I inhibitors in small-cell lung cancer.
    Fukuoka M
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):9-13. PubMed ID: 11497234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
    Saijo N; Horiike A
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):11-6. PubMed ID: 15255163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced NSCLC: new cytostatic agents.
    Kosmidis PA; Manegold C
    Lung Cancer; 2003 Aug; 41 Suppl 1():S123-32. PubMed ID: 12867071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixabepilone and the narrow path to developing new cytotoxic drugs.
    Gianni L
    J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970
    [No Abstract]   [Full Text] [Related]  

  • 19. Epothilones in prostate cancer: review of clinical experience.
    Dawson NA
    Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.